SB431542, a Selective Inhibitor of the TGF-β Type I Receptor, Enhances Doxorubicin Antitumor Activity via p63 Activation in Mutant p53 Breast Cancer Cells
SB431542 potentiates doxorubicin-induced apoptosis in <i>TP53</i>-mutant breast cancer cells by upregulating TAp63 and activating caspase-dependent pathways. These findings suggest that targeting the TGF-β/TAp63 signaling axis may offer a novel therapeutic approach to overcome chemoresistance in aggressive, <i>TP53</i>-mutant breast cancers.
Authors
- S. L. Chen
- H. T. Wang
- Y. C. Liu
- J. -H. Chen
- Yu-Ling null Kou
- Kuan-Yo null Wu
- Chia-Chi null Chen
- Yi-Ting null Cheng
- Tzu-Chi null Hsu
- Kuan-Yu null Lin
- Bi-He null Cai
Institutions
- E-Da Hospital (TW)
- I-Shou University (TW)
Publication Details
- Journal
- Frontiers in Bioscience-Landmark
- Published
- 2025-12-18
- DOI
- https://doi.org/10.31083/fbl45389
- Primary Topic
- TGF-β signaling in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00